0000899243-20-015868.txt : 20200609
0000899243-20-015868.hdr.sgml : 20200609
20200609202256
ACCESSION NUMBER: 0000899243-20-015868
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200608
FILED AS OF DATE: 20200609
DATE AS OF CHANGE: 20200609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Satter Muneer A
CENTRAL INDEX KEY: 0001315797
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38130
FILM NUMBER: 20953271
MAIL ADDRESS:
STREET 1: C/O SATTER INVESTMENT MANAGEMENT, LLC
STREET 2: 676 NORTH MICHIGAN AVENUE, SUITE 4000
CITY: CHICAGO
STATE: IL
ZIP: 60611
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC
CENTRAL INDEX KEY: 0001420565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 ARSENAL WAY
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-995-0900
MAIL ADDRESS:
STREET 1: 490 ARSENAL WAY
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-08
0
0001420565
AILERON THERAPEUTICS INC
ALRN
0001315797
Satter Muneer A
C/O SATTER MANAGEMENT CO., L.P.,
676 NORTH MICHIGAN AVENUE, SUITE 4000
CHICAGO
IL
60611
1
0
1
1
See Remarks
Common Stock
2020-06-08
4
P
0
3700000
1.10
A
7609449
I
See Footnote
Reflects shares that were purchased directly from the underwriter in an underwritten public offering conducted by the Issuer. The amount in Column 4 includes (a) 350,742 shares purchased by various trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares and (b) 3,349,258 shares purchased by Satter Medical Technology Partners, L.P. ("SMTP") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (a) and (b) of this footnote (1), except to the extent of his pecuniary interest.
The amount in Column 5 includes (a) 161,440 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 367,408 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest therein.
In connection with its original investment, SMTP had a contractual right to designate one member of the Board of Directors of Aileron Therapeutics, Inc. Therefore, the Reporting Person may be deemed to be a director by deputization.
/s/ Robert M. Hayward, P.C., attorney-in-fact for Muneer Satter
2020-06-09